The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial
Open accessAbstract
BACKGROUND: Barrett's esophagus is a premalignant condition that is a risk factor for the development of esophageal adenocarcinoma, a disease whose incidence is rapidly increasing. Because aspirin and other nonsteroidal anti-inflammatory drugs, such as celecoxib, may decrease the risk of developing esophageal cancer, we investigated the effect of long-term administration of celecoxib in patients with Barrett's esophagus with dysplasia. METHODS: Chemoprevention for Barrett's Esophagus Trial (CBET) is a phase IIb multicenter randomized placebo-controlled trial of celecoxib in patients with Barrett's esophagus and low- or high-grade dysplasia. Patients were randomly assigned to treatment with 200 mg of celecoxib or placebo, both administered orally twice daily, and then stratified by grade of dysplasia. The primary outcome was the change from baseline to 48 weeks of treatment in the proportion of biopsy samples with dysplasia between the celecoxib and placebo arms. Secondary and tertiary outcomes included evaluation of changes in histology and expression levels of relevant biomarkers. All statistical tests were two-sided. RESULTS: From April 1, 2000, through June 30, 2003, 222 patients were registered into CBET, and 100 of them with low- or high-grade Barrett's dysplasia were randomly assigned to treatment (49 to celecoxib and 51 to placebo). After 48 weeks of treatment, no difference was observed in the median change in the proportion of biopsy samples with dysplasia or cancer between treatment groups in either the low-grade (median change with celecoxib = -0.09, interquartile range [IQR] = -0.32 to 0.14 and with placebo = -0.07, IQR = -0.26 to 0.12; P = .64) or high-grade (median change with celecoxib = 0.12, IQR = -0.31 to 0.55, and with placebo = 0.02, IQR = -0.24 to 0.28; P = .88) stratum. No statistically significant differences in total surface area of the Barrett's esophagus; in prostaglandin levels; in cyclooxygenase-1/2 mRNA levels; or in methylation of tumor suppressor genes p16, adenomatous polyposis coli, and E-cadherin were found with celecoxib compared with placebo. CONCLUSIONS: Administration of 200 mg of celecoxib twice daily for 48 weeks of treatment does not appear to prevent progression of Barrett's dysplasia to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Cited by
Pennathur, A., Gibson, M. K., Jobe, B. A., & Luketich, J. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60643-6 · Cited by 2,390
Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus
Wang, K. K., & Sampliner, R. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01835.x · Cited by 2,014
Rustgi, A. K., & El-Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,243
American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.031 · Cited by 1,060
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis
Reid, B. J., Li, X., Galipeau, P. C., & Vaughan, T. L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2773 · Cited by 378
Metadata
- Authors
- Heath, E. I., Canto, M. I., Piantadosi, S., Montgomery, E., Weinstein, W. M., Herman, J. G., Dannenberg, A. J., Yang, V. W., Shar, A. O., Hawk, E., & Forastiere, A. A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-03
- Volume
- 99
- Issue
- 7
- Pages
- 545-557
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2169115304
- Cited by
- 178
- References
- 1
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. https://app.cochat.ai/papers/10.1093/jnci/djk112
- The paper
- Heath, E. I., Canto, M. I., Piantadosi, S., Montgomery, E., Weinstein, W. M., Herman, J. G., Dannenberg, A. J., Yang, V. W., Shar, A. O., Hawk, E., & Forastiere, A. A. (2007). Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djk112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.